

## Head and neck cancer

**Consultation on draft quality standard – deadline for comments** 17:00 on 14/10/2016 **email:** [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none"><li>1. Does this draft quality standard accurately reflect the key areas for quality improvement? If the systems and structures were available, do you think it would be possible to collect the data for the proposed quality measures? Do you have an example from practice of implementing the NICE guideline(s) that underpins this quality standard? If so, please submit your example to the <a href="#">NICE local practice collection</a> on the NICE website. Examples of using NICE quality standards can also be submitted.</li></ol>
<b>Organisation name – stakeholder or respondent</b> (if you are responding as an individual rather than a registered stakeholder please leave blank):	<b>[British HIV Association (BHIVA)]</b>
<b>Disclosure</b> Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.	[None]
<b>Name of commentator person completing form:</b>	[Professor Mark Bower, National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London]
<b>Supporting the quality standard</b> - Would your organisation like to express an interest in formally supporting this quality standard? <a href="#">More information.</a>	<b>[Answer Yes or No]</b>
<b>Type</b>	[office use only]

Please return to: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

Consultation on draft quality standard – deadline for comments 17:00 on 14/10/2016 email: [QSconsultations@nice.org.uk](mailto:QSconsultations@nice.org.uk)

Comment number	Section	Statement number	<p style="text-align: center;"><b>Comments</b></p> <p style="text-align: center;">Insert each comment in a new row. Do not paste other tables into this table because your comments could get lost – type directly into this table.</p>
1	Whole document		Need to test for HIV prior to commencing chemotherapy or radiotherapy (BHIVA guidelines for HIV-associated malignancies 2014, <i>HIV Medicine</i> (2014), <b>15</b> (Suppl. 2), 1–92.), as these cancer treatment modalities both have profound effects on CD4 counts. If the HIV is not diagnosed and treated and suitable prophylaxis given, patients will die from opportunistic infections and the cancer treatment will have contributed to these deaths.

**Checklist for submitting comments**

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include section number of the text each comment is about e.g. introduction; quality statement 1; quality statement 2 (measure).
- If commenting on a specific quality statement, please indicate the particular sub-section (for example, statement, measure or audience descriptor).
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons). We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance and quality standards that we have produced on topics related to this quality standard by checking [NICE Pathways](#).

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.